Our team has taken a novel approach to treating CIPN by taking advantage of our extensive experience with the G-protein linked Mas receptor and its agonist Ang-(1-7) to develop a platform of glycosylated Ang-(1-7) Mas receptor agonists including PNA5 and PNA6 that have outstanding brain penetration, enhanced bioavailability, decreased brain and peripheral inflammation, improved cerebral blood flow, and restored cognitive function in our preclinical vascular dementia and TBI animal models. The gene discussed is ANG; the disease is vascular dementia.